The evolving impact of microfabrication and nanotechnology on stent design

Journal of Vascular Surgery

Volumn 44, Issue 6, 2006, Pages 1363-1368

  Caves, Jeffrey M ^a   Chaikof, Elliot L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CHROMIUM; COBALT; DEXAMETHASONE; DOXORUBICIN; PACLITAXEL; RAPAMYCIN;

ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; BLOOD VESSEL WALL; CAROTID ARTERY INJURY; CLINICAL TRIAL; CORONARY STENT; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG ELUTING STENT; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENCAPSULATION; ENDOTHELIUM INJURY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MINIMALLY INVASIVE SURGERY; NANOPARTICLE; NANOTECHNOLOGY; NEEDLE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RABBIT; RESTENOSIS; REVASCULARIZATION; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY; GRAFT OCCLUSION, VASCULAR; HUMANS; NANOTECHNOLOGY; PACLITAXEL; PERIPHERAL VASCULAR DISEASES; PROSTHESIS DESIGN; SIROLIMUS; STENTS; THROMBOSIS;

EID: 36249004917     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.08.046     Document Type: Review

References (38)

1. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the national health and nutrition examination survey, 1999-2000. Circulation 110 (2004) 738-743
2. Garcia L.A. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther 13 Suppl 2 (2006) II3-II9
3. Centers for Disease Control and Prevention. Lower extremity disease among persons aged > or =40 years with and without diabetes-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54 (2005) 1158-1160
4. Centers for Disease Control and Prevention. Mobility limitation among persons aged > or =40 years with and without diagnosed diabetes and lower extremity disease-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54 (2005) 1183-1186
5. McDermott M.M., Guralnik J.M., Ferrucci L., Criqui M.H., Greenland P., Tian L., et al. Functional decline in lower-extremity peripheral arterial disease: Associations with comorbidity, gender, and race. J Vasc Surg 42 (2005) 1131-1137
6. Grimm J., Muller-Hulsbeck S., Jahnke T., Hilbert C., Brossmann J., and Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 12 (2001) 935-942
7. Wissgott C., Scheinert D., Rademaker J., Werk M., Schedel H., and Steinkamp H.J. Treatment of long superficial femoral artery occlusions with excimer laser angioplasty: long-term results after 48 months. Acta Radiol 45 (2004) 23-29
8. Zeller T., Rastan A., Schwarzwalder U., Frank U., Burgelin K., Amantea P., et al. Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device. J Vasc Interv Radiol 15 (2004) 1391-1397
9. Laird J.R. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 13 Suppl 2 (2006) II30-II40
10. Muradin G.S., Bosch J.L., Stijnen T., and Hunink M.G. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 221 (2001) 137-145
11. Schillinger M., Exner M., Mlekusch W., Haumer M., Rumpold H., Ahmadi R., et al. Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology 227 (2003) 419-425
12. Duda S.H., Bosiers M., Lammer J., Scheinert D., Zeller T., Tielbeek A., et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 16 (2005) 331-338
13. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting taxus stent: The TAXUS-IV trial. Circulation 109 (2004) 1942-1947
14. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
15. Henry M., Polydorou A., Henry I., Ad Polydorou I., Hugel I.M., and Anagnostopoulou S. Angioplasty and stenting of extracranial vertebral artery stenosis. Int Angiol 24 (2005) 311-324
16. Schillinger M., Sabeti S., Loewe C., Dick P., Amighi J., Mlekusch W., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354 (2006) 1879-1888
17. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
18. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
19. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
20. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
21. Aoki J., Ong A.T., Rodriguez Granillo G.A., McFadden E.P., van Mieghem C.A., Valgimigli M., et al. "Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 150 (2005) 994-999
22. Finkelstein A., McClean D., Kar S., Takizawa K., Varghese K., Baek N., et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107 (2003) 777-784
23. Murali M., and Yeo S.H. Rapid biocompatible micro device fabrication by micro electro-discharge machining. Biomed Microdevices 6 (2004) 41-45
24. Takahata K., and Gianchandani K.T. A planar approach for manufacturing cardic stents: design, fabrication, and mechanical evaluation. J Microelectromech Syst 13 (2004) 933-939
25. Reed M.L., Wu C., Kneller J., Watkins S., Vorp D.A., Nadeem A., et al. Micromechanical devices for intravascular drug delivery. J Pharm Sci 87 (1998) 1387-1394
26. Henry S., McAllister D.V., Allen M.G., and Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci 87 (1998) 922-925
27. McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A 100 (2003) 13755-13760
28. Miller D.C., Thapa A., Haberstroh K.M., and Webster T.J. Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features. Biomaterials 25 (2004) 53-61
29. Miller D.C., Haberstroh K.M., and Webster T.J. Mechanism(s) of increased vascular cell adhesion on nanostructured poly(lactic-co-glycolic acid) films. J Biomed Mater Res A 73 (2005) 476-484
30. Liu D.M., Troczynski T., and Tseng W.J. Water-based sol-gel synthesis of hydroxyapatite: process development. Biomaterials 22 (2001) 1721-1730
31. Liu D.M., Yang Q., and Troczynski T. Sol-gel hydroxyapatite coatings on stainless steel substrates. Biomaterials 23 (2002) 691-698
32. Areva S., Paldan H., Peltola T., Narhi T., Jokinen M., and Linden M. Use of sol-gel-derived titania coating for direct soft tissue attachment. J Biomed Mater Res A 70 (2004) 169-178
33. Guzman L.A., Labhasetwar V., Song C., Jang Y., Lincoff A.M., Levy R., et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94 (1996) 1441-1448
34. Labhasetwar V., Song C., Humphrey W., Shebuski R., and Levy R.J. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci 87 (1998) 1229-1234
35. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106 (2002) 2842-2847
36. Wickline S.A., Neubauer A.M., Winter P., Caruthers S., and Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26 (2006) 435-441
37. Uwatoku T., Shimokawa H., Abe K., Matsumoto Y., Hattori T., Oi K., et al. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ Res 92 (2003) e62-e69
38. Kolodgie F.D., John M., Khurana C., Farb A., Wilson P.S., Acampado E., et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106 (2002) 1195-1198